India's Cipla Q3 net up 25.5 pct
MUMBAI Feb 6 (Reuters) - Cipla Ltd, India's fifth largest drugmaker by sales, reported a 25.5 percent rise in quarterly profit on robust sales but slightly missed street estimates as taxes surged.
The Mumbai-based drugmaker said, net profit grew to 3.39 billion rupees ($63.81 million) in October-December from 2.7 billion rupees a year earlier. Analysts on an average had expected a net profit of 3.48 billion rupees, according to Thomson Reuters I/B/E/S.
Sales rose 18.65 percent to 20.3 billion rupees, it said.
Shares in Cipla fell 0.56 percent to 405 rupees on Wednesday when the Mumbai market closed down 0.1 percent. ($1 = 53.12 rupees) (Reporting by Kaustubh Kulkarni; Editing by Anand Basu)
- Tweet this
- Share this
- Digg this
- India threatens to derail WTO deal, prompts angry U.S. rebuke
- Facebook says SEC's IPO probe ends, extending WhatsApp closing date
- Israel says ready to extend short Gaza truce; many bodies pulled from rubble
- Russia criticises EU sanctions, raps U.S. over Ukraine role
- UPDATE 4-Russia criticises EU sanctions, raps US over Ukraine role
New Prime Minister Narendra Modi is facing criticism for remaining silent about incidents deemed anti-Muslim in the past week, underscoring fears that his Hindu nationalist followers will upset religious relations in the multi-faith nation. Full Article
Amazon's far-reaching ambitions, lack of profits, unnerve investors Full Article